

FIRST REGULAR SESSION

[PERFECTED]

HOUSE COMMITTEE SUBSTITUTE FOR

HOUSE BILL NOS. 593 & 695

97TH GENERAL ASSEMBLY

1605H.04P

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To amend chapter 338, RSMo, by adding thereto one new section relating to the Missouri oral chemotherapy parity interim committee.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Chapter 338, RSMo, is amended by adding thereto one new section, to be
2 known as section 338.321, to read as follows:

338.321. 1. The “**Missouri Oral Chemotherapy Parity Interim Committee**” is
2 hereby created to study the disparity in patient co-payments between orally and
3 intravenously administered chemotherapies, the reasons for the disparity, and the patient
4 benefits in establishing co-payment parity between oral and infused chemotherapy agents.
5 The committee shall consider information on the costs or actuarial analysis associated with
6 the delivery of patient oncology treatments. The conclusions of this study shall satisfy any
7 statutorily required actuarial analysis.

8 2. The Missouri oral chemotherapy parity interim committee shall consist of the
9 following members:

10 (1) Two members of the senate, appointed by the president pro tempore of the
11 senate;

12 (2) Two members of the house of representatives, appointed by the speaker of the
13 house of representatives;

14 (3) One member who is an oncologist or physician with expertise in the practice of
15 oncology licensed in this state under chapter 334;

16 (4) One member who is an oncology nurse licensed in this state under chapter 335;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

17 **(5) One member who is a representative of a Missouri pharmacy benefit**
18 **management company;**

19 **(6) One member from an organization representing licensed pharmacists in this**
20 **state;**

21 **(7) One member from the business community representing businesses on health**
22 **insurance issues;**

23 **(8) One member from an organization representing the leading research-based**
24 **pharmaceutical and biotechnology companies;**

25 **(9) One patient advocate;**

26 **(10) One member from the organization representing a majority of hospitals in this**
27 **state;**

28 **(11) One member from a health carrier as such term is defined under section**
29 **376.1350;**

30 **(12) One member from the organization representing a majority of health carriers**
31 **in this state, as such term is defined under section 376.1350;**

32 **(13) One member from the Leukemia and Lymphoma Society; and**

33 **(14) The director of the department of insurance, financial institutions and**
34 **professional registration, who shall chair the committee.**

35 **3. All members, except for the members from the general assembly, shall be**
36 **appointed by the governor no later than September 1, 2013. The department of insurance,**
37 **financial institutions and professional registration shall provide assistance to the**
38 **committee.**

39 **4. No later than January 1, 2014, the committee shall submit a report to the**
40 **governor, the speaker of the house of representatives, the president pro tempore of the**
41 **senate, and the appropriate legislative committee of the general assembly regarding the**
42 **results of the study and any legislative recommendations.**

✓